share_log

Novavax | DEFA14A: Others

Novavax | DEFA14A: Others

诺瓦瓦克斯医药 | DEFA14A:其他
美股sec公告 ·  04/29 08:03
Moomoo AI 已提取核心信息
Novavax, Inc., a biotechnology company known for its vaccine development, has filed a definitive proxy statement with the United States Securities and Exchange Commission (SEC). The filing, made under Schedule 14A, is a requirement for companies that are soliciting shareholder votes. Novavax has confirmed that the proxy statement is definitive, indicating that it contains all the necessary information for shareholders to make informed decisions regarding the matters to be voted on. The company has also noted that no filing fee is required for this submission.
Novavax, Inc., a biotechnology company known for its vaccine development, has filed a definitive proxy statement with the United States Securities and Exchange Commission (SEC). The filing, made under Schedule 14A, is a requirement for companies that are soliciting shareholder votes. Novavax has confirmed that the proxy statement is definitive, indicating that it contains all the necessary information for shareholders to make informed decisions regarding the matters to be voted on. The company has also noted that no filing fee is required for this submission.
以疫苗开发闻名的生物技术公司Novavax, Inc. 已向美国证券交易委员会(SEC)提交了最终委托书。该文件是根据附表14A提交的,是向股东征集选票的公司的要求。Novavax已确认委托书是最终的,表明该委托书包含所有必要的信息,使股东可以就有待表决的事项做出明智的决定。该公司还指出,此次提交不需要任何申请费。
以疫苗开发闻名的生物技术公司Novavax, Inc. 已向美国证券交易委员会(SEC)提交了最终委托书。该文件是根据附表14A提交的,是向股东征集选票的公司的要求。Novavax已确认委托书是最终的,表明该委托书包含所有必要的信息,使股东可以就有待表决的事项做出明智的决定。该公司还指出,此次提交不需要任何申请费。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息